// App-Quantinova.ai

1372 : Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy

Researchers

Presenter

  • Donna E. Hogge

Principal Investigators

  • Scott Weir

  • Hong Chang

  • Joseph M. Brandwein

  • Vikas Gupta

  • Andre C. Schuh

  • Suzanne Trudel

  • Karen W.L. Yee

  • Greg Reed

  • Aaron D Schimmer

  • Jim Kasper

  • Lavonne Patton

  • Yulia Jitkova

  • Marcela Gronda

  • Rose Hurren

  • Lian Rajewski

  • Kevin Schorno

Medical Centers

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Ontario, Canada

  • Division of Hematology, University of British Columbia, Vancouver, BC, Canada

  • McLaughlin Centre for Molecular Medicine, Princess Margaret Hospital, Toronto, ON, Canada

  • Laboratory Genetics, University Health Network, Toronto, ON, Canada

Locations

  • Canada

Companies

  • Beckloff Associates

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

  • Myelodysplastic Syndrome

  • Neutropenia

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Ciclopirox

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • NA

Study Id's

  • NCT00990587

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved